参考文献/References:
目的观察紫杉醇联合卡培他滨治疗晚期胃癌的疗效及毒副反应。方法采用紫杉醇80 mg.m-2静脉滴注3 h,第1、8天;卡培他滨1 000 mg.m-2,每日2次,第1~14天。21 d为1个周期,连用2个周期后评价疗效,有效病例4周后确认。结果 38例中获得完全缓解3例(7.9%),部分缓解16例(42.1%),稳定13例(34.2%),进展6例(15.8%),有效率50.0%。主要药物不良反应为骨髓抑制及胃肠道反应,多为Ⅰ度和Ⅱ度毒副反应,其他有脱发、手足综合征和肌肉酸痛等,所有患者无化学治疗相关死亡。结论紫杉醇联合卡培他滨治疗晚期胃癌疗效确切,安全性好,不良反应可耐受。
相似文献/References:
[1]张占东,郑育娟,袁媛,等.奥沙利铂联合卡培他滨新辅助化学疗法治疗中晚期胃癌疗效观察[J].新乡医学院学报,2012,29(09):703.
[2]王荦楠杨 萌崔艳慧张清琴,苗战会李小瑞,寇小格.奥沙利铂联合卡培他滨治疗晚期肝细胞癌的疗效及安全性 [J].新乡医学院学报,2012,29(10):787.
[3]丁 锋,张清会.厄洛替尼联合紫杉醇和顺铂治疗晚期非小细胞肺癌疗效观察[J].新乡医学院学报,2018,35(6):513.[doi:10.7683/xxyxyxb.2018.06.016]
DING Feng,ZHANG Qing-hui.Effect of erlotinib combined with paclitaxel and cisplatin in treatment of advanced non-small cell lung cancer[J].Journal of Xinxiang Medical University,2018,35(01):513.[doi:10.7683/xxyxyxb.2018.06.016]
[4]常 伟,丁 敏,周建华,等.曲妥珠单抗联合紫杉醇治疗人表皮生长因子受体-2过表达转移性乳腺癌的疗效和安全性评价[J].新乡医学院学报,2018,35(6):517.[doi:10.7683/xxyxyxb.2018.06.017]
CHANG Wei,DING Min,ZHOU Jian-hua,et al.Efficacy and safety of trastuzumab combined with paclitaxel for treatment of human epidermal growth factor receptor-2 overexpressing metastatic breast cancer patients[J].Journal of Xinxiang Medical University,2018,35(01):517.[doi:10.7683/xxyxyxb.2018.06.017]
[5]李 果,王世进.阿帕替尼联合紫杉醇治疗复发性耐药型上皮性卵巢癌疗效观察[J].新乡医学院学报,2022,39(4):341.[doi:10.7683/xxyxyxb.2022.04.008]
LI Guo,WANG Shijin.Efficacy of apatinib combined with paclitaxel in the treatment of recurrent drug-resistant epithelial ovarian cancer[J].Journal of Xinxiang Medical University,2022,39(01):341.[doi:10.7683/xxyxyxb.2022.04.008]
[6]李小峰,孙新宇,张 慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(01):376.[doi:10.7683/xxyxyxb.2022.04.016]